Company intelligence / Profile preview

AquaPass Medical

Ownership: Private
Development stage: Other

Overview

The AquaPass System has demonstrated safety and efficacy in early clinical studies. It enables significant fluid removal (>850 mL per session), with no reported hospitalizations for fluid overload or worsening of renal function. Patients report high compliance and preference over IV diuretics. Clinical benefits include reduced NT-ProBNP levels and improved congestion scores. No 180-day mortality or 30-day readmissions were observed in the proof-of-concept study cohort

Therapeutic areas: NephrologyEndocrinologyCardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on AquaPass Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AquaPass Medical.

Explore the full profile